Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.65 |
| ▸ | HTR3B | O95264 | 3/20 | 0.65 |
| ▸ | HTR3A | P46098 | 3/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23355832 | 0.98 | ADRB1 (0.63) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL22638136 | 0.98 | ADRB1 (0.63) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14922261 | 0.95 | ADRB1 (0.59) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20907431 | 0.94 | CHRNB2 (0.70) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6132814 | 0.91 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29749541 | 0.89 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17455228 | 0.85 | ADRB1 (0.67) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8811069 | 0.85 | ADRB1 (0.62) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8551038 | 0.85 | ADRB1 (0.62) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7083865 | 0.84 | ADRB1 (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| CN-110742893-B | Methods of treating cancer with A2A receptor antagonists | 百济神州(北京)生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023191400-A1 | ETHYL PIPERIDINE TRIAZOLO TRIAZINE DERIVATIVES, SYNTHESIS METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF CANCER | 에이치케이이노엔 주식회사 | 2023-10-05 | — | — | WO | disclosed |
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS | 2022-07-28 | — | — | US | disclosed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-110922408-B | 3H- [1,2,3] triazolo [4,5-d ] pyrimidin-5-amine derivatives and uses thereof | 广东东阳光药业有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | disclosed |
| US-20030212080-A1 | Adenosine A2a receptor antagonists | SCHERING CORPORATION | 2003-11-13 | — | — | US | disclosed |
| CN-1451007-A | Adenosine A2aReceptor antagonists | SCHERING CORP (US) | 2003-10-22 | — | — | CN | disclosed |
| US-20030191130-A1 | [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists | SCHERING CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6630475-B2 | 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease | SCHERING CORPORATION | 2003-10-07 | — | — | US | disclosed |
| WO-2003048163-A1 | [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048164-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1283839-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| WO-2001092264-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | ADRB1 335/4885HTR3E 122/4885HTR3B 57/4885 |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | ADRB1 51/4885HTR3E 67/4885HTR3B 36/4885 |
| US-12325708-B2 | Adenosine 2 receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ADRB1 335/4885HTR3E 122/4885HTR3B 57/4885 |
| US-20030191130-A1 | [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADRB1 23/4885HTR3E 53/4885HTR3B 31/4885 |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | ADRB1 35/4885HTR3E 52/4885HTR3B 30/4885 |
| US-20030212080-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADRB1 24/4885HTR3E 47/4885HTR3B 33/4885 |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | ADRB1 35/4885HTR3E 66/4885HTR3B 40/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | ADRB1 19/4885HTR3E 121/4885HTR3B 65/4885 |
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | ADORA2A, ADORA3, ADORA2B | ADRB1 46/4885HTR3E 68/4885HTR3B 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.